{
  "id": "mhgap#risk_safety_66313db9",
  "content": "y Recurrence/relapse rate of any mood episode: episodes:\n– For this outcome, almost all medicines – For this outcome all medicines outperformed\nreduced relapse: asenapine, aripiprazole plus placebo except aripiprazole plus sodium\nsodium valproate, lithium plus oxcarbazepine, valproate, carbamazepine, lamotrigine, and\nolanzapine, lithium plus sodium valproate, lamotrigine plus sodium valproate.\naripiprazole plus lamotrigine, aripiprazole – Asenapine ranked first, aripiprazole once monthly\nonce monthly, quetiapine, lithium, risperidone ranked second and lithium plus oxcarbazepine\nLAI, sodium valproate and lamotrigine all ranked third.\noutperformed placebo. – The certainty of the evidence was very low\n– Asenapine ranked first, aripiprazole plus to moderate.\nsodium valproate ranked second and lithium y Adverse effects:\nplus oxcarbazepine ranked third in terms\n– With regard to the outcome “discontinuation due\nof recurrent/relapse.\nto adverse effects”, lithium plus sodium valproate\n– The certainty of the evidence was low had significantly higher discontinuation rates\nto moderate. than placebo.\ny Recurrence/relapse of depressive episodes: – Only asenapine showed a lower discontinuation\n– Aripiprazole plus sodium valproate, lamotrigine, rate than placebo.\nlamotrigine plus sodium valproate, lithium, y Due to the high risk of teratogenic effect with\nolanzapine, and quetiapine outperformed sodium valproate, the GDG believed it was important",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety y Recurrence/relapse rate of any mood episode: episodes:\n– For this outcome, almost all medicines – For this outcome all medicines outperformed\nreduced relapse: asenapine, aripiprazole plus placebo except aripiprazole plus sodium\nsodium valproate, lithium plus oxcarbazepine, valproate, carbamazepine, lamotrigine, and\nolanzapine, lithium plus sodium valproate, lamotrigine plus sodium valproate.\naripiprazole plus lamotrigine, aripiprazole – Asenapine ranked first, aripiprazole once monthly\nonce monthly, quetiapine, lithium, risperidone ranked second and lithium plus oxcarbazepine\nLAI, sodium valproate and lamotrigine all ranked third.\noutperformed placebo. – The certainty of the evidence was very low\n– Asenapine ranked first, aripiprazole plus to moderate.\nsodium valproate ranked second and lithium y Adverse effects:\nplus oxcarbazepine ranked third in terms\n– With regard to the outcome “discontinuation due\nof recurrent/relapse.\nto adverse effects”, lithium plus sodium valproate\n– The certainty of the evidence was low had significantly higher discontinuation rates\nto moderate. than placebo.\ny Recurrence/relapse of depressive episodes: – Only asenapine showed a lower discontinuation\n– Aripiprazole plus sodium valproate, lamotrigine, rate than placebo.\nlamotrigine plus sodium valproate, lithium, y Due to the high risk of teratogenic effect with\nolanzapine, and quetiapine outperformed sodium valproate, the GDG believed it was important Y recurrence/relapse rate of any mood episode: episodes:\n– for this outcome, almost all medicines – for this outcome all medicines outperformed\nreduced relapse: asenapine, aripiprazole plus placebo except aripiprazole pl..."
}